Reduction in Alveolar Macrophage Size in Refractory Autoimmune Pulmonary Alveolar Proteinosis After Treatment With Pioglitazone

J Bronchology Interv Pulmonol. 2020 Jul;27(3):219-222. doi: 10.1097/LBR.0000000000000686.

Authors

Daniel C Vis¹, Margaret M Kelly², Elaine De Heuvel², Paul R MacEachern¹

Affiliations

¹ Departments of Medicine.
² Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada.

PMID: 32569076
DOI: 10.1097/LBR.0000000000000686

No abstract available

Publication types

Case Reports

MeSH terms

Autoimmune Diseases / blood
Autoimmune Diseases / drug therapy*
Autoimmune Diseases / immunology*
Autoimmune Diseases / pathology
Bronchoalveolar Lavage Fluid / immunology
Fibrosis / diagnostic imaging
Granulocyte-Macrophage Colony-Stimulating Factor / antagonists & inhibitors
Humans
Hypoglycemic Agents / administration & dosage
Hypoglycemic Agents / therapeutic use*
Informed Consent / legislation & jurisprudence
Macrophages, Alveolar / drug effects*
Male
Middle Aged
Off-Label Use / legislation & jurisprudence
Pioglitazone / administration & dosage
Pioglitazone / therapeutic use*
Pulmonary Alveolar Proteinosis / blood
Pulmonary Alveolar Proteinosis / drug therapy*
Pulmonary Alveolar Proteinosis / immunology*
Pulmonary Alveolar Proteinosis / pathology
Treatment Outcome

Substances

Hypoglycemic Agents
Granulocyte-Macrophage Colony-Stimulating Factor
Pioglitazone

Supplementary concepts

Pulmonary Alveolar Proteinosis, Acquired